Jump Financial LLC Has $1.80 Million Stake in Amneal Pharmaceuticals, Inc. $AMRX

Key Points

• Jump Financial LLC increased its holdings in AMNEAL PHARMACEUTICALS by 29.2% during the first quarter, owning a total of 214,375 shares worth approximately $1.8 million.
• Several institutional investors, including BlackBarn Capital Partners LP and Hsbc Holdings PLC, also boosted their stakes, indicating growing institutional interest in AMNEAL PHARMACEUTICALS.
• Brokerages have set an average price target of $11.60 for AMNEAL, with the Goldman Sachs Group initiating coverage with a "buy" rating and a $12.00 target.

Jump Financial LLC lifted its stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 29.2% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 214,375 shares of the company's stock after purchasing an additional 48,459 shares during the quarter. Jump Financial LLC owned 0.07% of Amneal Pharmaceuticals worth $1,796,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also modified their holdings of the stock. GAMMA Investing LLC increased its holdings in shares of Amneal Pharmaceuticals by 5,975.0% during the 1st quarter. GAMMA Investing LLC now owns 3,159 shares of the company's stock valued at $26,000 after acquiring an additional 3,107 shares during the last quarter. Headlands Technologies LLC bought a new stake in Amneal Pharmaceuticals in the 1st quarter valued at $31,000. Amalgamated Bank increased its holdings in shares of Amneal Pharmaceuticals by 33.0% during the 1st quarter. Amalgamated Bank now owns 5,511 shares of the company's stock worth $46,000 after purchasing an additional 1,367 shares during the period. GF Fund Management CO. LTD. bought a new position in shares of Amneal Pharmaceuticals during the 4th quarter worth about $52,000. Finally, Xponance Inc. lifted its position in shares of Amneal Pharmaceuticals by 16.1% during the 1st quarter. Xponance Inc. now owns 13,183 shares of the company's stock worth $110,000 after buying an additional 1,828 shares during the period. 31.82% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently commented on AMRX shares. The Goldman Sachs Group began coverage on Amneal Pharmaceuticals in a report on Friday, June 6th. They set a "buy" rating and a $12.00 target price on the stock. Wall Street Zen lowered Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Tuesday, May 13th. Five investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $11.60.

Insider Buying and Selling

In other news, EVP Nikita Shah sold 6,340 shares of the stock in a transaction that occurred on Monday, August 25th. The stock was sold at an average price of $9.50, for a total value of $60,230.00. Following the completion of the sale, the executive vice president owned 146,403 shares of the company's stock, valued at approximately $1,390,828.50. This represents a 4.15% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director John Kiely sold 32,000 shares of the business's stock in a transaction that occurred on Wednesday, August 27th. The stock was sold at an average price of $9.23, for a total value of $295,360.00. Following the transaction, the director directly owned 225,433 shares in the company, valued at $2,080,746.59. The trade was a 12.43% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 609,206 shares of company stock worth $5,700,625. 17.45% of the stock is owned by corporate insiders.

Amneal Pharmaceuticals Stock Up 0.1%

Amneal Pharmaceuticals stock traded up $0.01 during mid-day trading on Monday, hitting $9.56. 2,493,976 shares of the company's stock were exchanged, compared to its average volume of 1,702,922. The firm has a market capitalization of $3.00 billion, a P/E ratio of 956.96 and a beta of 1.19. Amneal Pharmaceuticals, Inc. has a fifty-two week low of $6.68 and a fifty-two week high of $9.79. The company's 50 day simple moving average is $8.52 and its 200-day simple moving average is $8.07.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported $0.23 EPS for the quarter, topping the consensus estimate of $0.17 by $0.06. Amneal Pharmaceuticals had a net margin of 0.12% and a negative return on equity of 189.49%. Amneal Pharmaceuticals has set its FY 2025 guidance at 0.700-0.750 EPS. Research analysts expect that Amneal Pharmaceuticals, Inc. will post 0.53 EPS for the current year.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.